The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …

The serotonin deficit hypothesis explanation for major depressive disorder (MDD) has
persisted among clinicians and the general public alike despite insufficient supporting …

Ketamine is a dissociative anesthetic that induces a shift in global consciousness states and
related brain dynamics. Portable low-density EEG systems could be used to monitor these …

Ketamine is an effective antidepressant, but there is substantial variability in patient
response and the precise mechanism of action is unclear. Neuroimaging can provide …

Previous studies have shown an association between the thalamocortical dysconnectivity
and treatment-resistant depression (TRD). Whether a single subanesthetic dose of ketamine …

Ketamine produces fast‐acting antidepressant effects in treatment resistant depression
(TRD). Though prior studies report ketamine‐related changes in brain activity in TRD …

Borderline personality disorder (BPD) is diagnosed in 10-30% of patients with major
depressive disorder (MDD), and the frequency of MDD among individuals with BPD reaches …

Introduction Ketamine treatment prompts a rapid antidepressant response in treatment-
resistant depression (TRD). We performed an exploratory investigation of how ketamine …

Ketamine, an N-methyl-D-aspartate receptor antagonist, is a racemic mixture of esketamine
and arketamine used to treat unipolar and bipolar depression. Preliminary reports indicate …

Background: Esketamine is a version of ketamine that has been approved for treatment-
resistant depression, but our previous studies showed a link between non-medical use of …